AMLX

#2013
Amylyx Pharmaceuticals, Inc. Common Stock
16.92 USD
+2.73%
版块: 医疗保健
基础: USD
利润货币: USD
日范围
16.92
16.92
年范围
3.79
17.49
日变化
+2.73%
每月变动
+19.24%
6个月变化
+15.89%
年变化
+332.74%
前一天收盘价
16.47
开盘价
16.92
买价
卖价
最低价
16.92
High
16.92
交易量
87
展开完整图表

Financials

概览 声明 统计 股息
每季度 年度
  • Market Capitalization 1.87 B
  • Employee 136
  • Founded 2013
  • CEO N/A
  • Website www.amylyx.com
  • Headquarter Delaware, United States
  • FIGI BBG00DP10YT5
  • Industry Technology
总收入
净利润
每股基本收益（基本 EPS）
总债务
自由现金流
现金及现金等价物
市盈率
-7.9
市销率
—

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.

新闻